DYRK2
MOLECULAR TARGETdual specificity tyrosine phosphorylation regulated kinase 2
DYRK2 (dual specificity tyrosine phosphorylation regulated kinase 2) is targeted by 34 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).
Compounds Targeting DYRK2
Ranked by bioassay confidence score (PubChem active assay count × evidence quality).
| # | Compound | Confidence | Active Assays |
|---|---|---|---|
| 1 | erlotinib | 5.55 | 256 |
| 2 | epigalocatechin gallate | 5.40 | 220 |
| 3 | seliciclib | 4.91 | 135 |
| 4 | foretinib | 4.34 | 76 |
| 5 | ruxolitinib | 4.23 | 68 |
| 6 | pi 103 | 4.17 | 64 |
| 7 | silmitasertib | 3.78 | 43 |
| 8 | abemaciclib | 3.66 | 38 |
| 9 | canertinib | 3.53 | 33 |
| 10 | 6bio | 3.50 | 32 |
| 11 | bms 387032 | 3.47 | 31 |
| 12 | at 7519 | 3.33 | 27 |
| 13 | dovitinib | 3.09 | 21 |
| 14 | at 9283 | 3.09 | 21 |
| 15 | lestaurtinib | 3.04 | 20 |
| 16 | r 406 | 2.83 | 16 |
| 17 | Harmine Alkaloid isolated from seeds of PEGANUM HARMALA; ZYGOPHYLLACEAE. It is identical to banisterine, or telepathine, from Banisteria caapi and is | 2.77 | 15 |
| 18 | plx 4720 | 2.71 | 14 |
| 19 | bms 345541 | 2.71 | 14 |
| 20 | kw 2449 | 2.64 | 13 |
| 21 | ast 487 | 2.56 | 12 |
| 22 | berzosertib | 2.30 | 9 |
| 23 | su 014813 | 2.20 | 8 |
| 24 | leucettamine b | 2.20 | 8 |
| 25 | tg100 115 | 2.08 | 7 |
| 26 | zemirciclib | 2.08 | 7 |
| 27 | harmol | 2.08 | 7 |
| 28 | demethylbellidifolin | 1.95 | 6 |
| 29 | lorecivivint | 1.79 | 5 |
| 30 | egcg | 0.69 | 1 |
| 31 | Afatinib | 0.69 | 1 |
| 32 | Crizotinib | 0.69 | 1 |
| 33 | pictilisib | 0.69 | 1 |
| 34 | sp600125 | 0.69 | 1 |
About DYRK2 as a Drug Target
DYRK2 (dual specificity tyrosine phosphorylation regulated kinase 2) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 34 compounds with documented DYRK2 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.
DYRK2 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.